The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

The Safety of Novel Therapies in Chronic Lymphocytic Leukemia in the Era of Intermittent Fasting: A Pharmacology-Based Review

<p dir="ltr">Intermittent fasting (IF) has recently gained popularity due to its emerging benefits in reducing weight and improving metabolic health. Concurrently, novel agents (NAs) like venetoclax and Bruton tyrosine kinase inhibitors (BTKIs) have revolutionized the treatment of ch...

Full description

Saved in:
Bibliographic Details
Main Author: Maria Benkhadra (19756941) (author)
Other Authors: Nuha Fituri (19756944) (author), Soha Aboukhalaf (19756947) (author), Rola Ghasoub (16555851) (author), Mervat Mattar (17430972) (author), Khalil Alfarsi (17430975) (author), Salem Alshemmari (19756950) (author), Mohamed A. Yassin (8361183) (author)
Published: 2024
Subjects:
Biomedical and clinical sciences
Oncology and carcinogenesis
chronic lymphocytic leukemia
tumor lysis syndrome
gastrointestinal bleeding
intermittent fasting
fluid-restricted intermittent fasting
fluid-liberal intermittent fasting
Bruton tyrosine kinase inhibitors (BTK)
BCL2 inhibitors
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items